Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

Shenzhen Geno-Immune Medical Institute is the lead sponsor of 43 current clinical trials in our China register. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 1/2. The drugs named most often in its trials are Clonal fetal MSCs. The most-studied condition is Acute Myeloid Leukemia.

ClinicalTrials.gov trials by status

Not yet open4298%
By invitation12%

Trials by phase

Phase 1/22865%
Phase 1921%
Not applicable614%

Clinical trials sponsored by Shenzhen Geno-Immune Medical Institute

43 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
IT and IV Lentiviral Gene Therapy for X-ALD NCT03727555 · ClinicalTrials.gov ↗ · X-linked Adrenoleukodystrophy	Not applicable	Not yet open	2027-06	China
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma NCT06429150 · ClinicalTrials.gov ↗ · Multiple Myeloma, Plasmacytoma	Phase 1/2	Not yet open	2026-12	China
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD NCT07046338 · ClinicalTrials.gov ↗ · Metachromatic Leukodystrophy (MLD)	Not applicable	Not yet open	2027-06	China
Combination Immunotherapy Targeting Sarcomas NCT04433221 · ClinicalTrials.gov ↗ · Sarcoma, Osteoid Sarcoma, Ewing Sarcoma	Phase 1/2	Not yet open	2027-07	China
CD19/70 Bi-specific CAR-T Cell Therapy NCT05436496 · ClinicalTrials.gov ↗ · B Cell Malignancies	Phase 1/2	Not yet open	2027-06	China
4SCAR19U T Cells Targeting B Cell Malignancies NCT05995015 · ClinicalTrials.gov ↗ · B Cell Malignancies	Phase 1	Not yet open	2026-12	China
Universal CAR-T Cells Targeting AML NCT05995041 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 1	Not yet open	2027-06	China
DLL3 CAR-T Therapy Targeting Brain Tumors NCT07180927 · ClinicalTrials.gov ↗ · Glioblastoma of Cerebellum	Phase 1/2	Not yet open	2027-06	China
GD2/PSMA Bi-specific CAR-T Cell Therapy NCT05437315 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Not yet open	2026-12	China
Multi-4SCAR-T Therapy Targeting Breast Cancer NCT04430595 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1/2	Not yet open	2027-06	China
PSMA-specific CAR-T Cell Therapy NCT04429451 · ClinicalTrials.gov ↗ · PSMA Positive Tumors or Tumor Tissues	Phase 1/2	Not yet open	2026-12	China
Lentiviral Gene Therapy for CGD NCT03645486 · ClinicalTrials.gov ↗ · Chronic Granulomatous Disease	Not applicable	Not yet open	2027-07	China
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies NCT04033302 · ClinicalTrials.gov ↗ · T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia	Phase 1/2	Not yet open	2026-12	China
Immune Modulatory DC Vaccine Against Brain Tumor NCT03914768 · ClinicalTrials.gov ↗ · Diffuse Intrinsic Pontine Glioma or Glioblastoma	Phase 1	Not yet open	2026-12	China
Engineered Dendritic Cell Vaccines for Multiple Myeloma NCT06435910 · ClinicalTrials.gov ↗ · Multiple Myeloma or Plasmacytoma	Phase 1	Not yet open	2027-06	China
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector NCT03351829 · ClinicalTrials.gov ↗ · Beta-Thalassemia	Not applicable	Not yet open	2026-12	China
Study on GD2 Positive Solid Tumors by 4SCAR-GD2 NCT02992210 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Not yet open	2026-12	China
Multi-CAR-T Cells Targeting B Cell Lymphomas NCT04429438 · ClinicalTrials.gov ↗ · B Cell Lymphoma (BCL)	Phase 1/2	Not yet open	2027-06	China
CAR-T Immunotherapy Targeting CD19- ALL NCT04016129 · ClinicalTrials.gov ↗ · B-cell Leukemia	Phase 1/2	Not yet open	2027-07	China
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells NCT06435897 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Phase 1/2	Not yet open	2027-06	China
Lentiviral FIX Gene Therapy NCT03961243 · ClinicalTrials.gov ↗ · Hemophilia B	Phase 1	Not yet open	2027-06	China
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma NCT03271632 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Not yet open	2026-12	China
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 NCT04432649 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Not yet open	2027-06	China
Lentiviral FVIII Gene Therapy NCT03217032 · ClinicalTrials.gov ↗ · Hemophilia A	Phase 1	Not yet open	2027-06	China
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas NCT03356782 · ClinicalTrials.gov ↗ · Sarcoma, Osteoid Sarcoma, Ewing Sarcoma	Phase 1/2	Not yet open	2027-06	China
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) NCT03645460 · ClinicalTrials.gov ↗ · Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)	Not applicable	Not yet open	2027-06	China
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia NCT03222674 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 1/2	Not yet open	2026-12	China
CAR-T Cells Targeting Autoimmune Diseases NCT05459870 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Phase 1/2	Not yet open	2027-06	China
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma NCT04637503 · ClinicalTrials.gov ↗ · Neuroblastoma	Phase 1/2	Not yet open	2026-12	China
CD19/22 Bi-specific CAR-T Cell Therapy NCT05432882 · ClinicalTrials.gov ↗ · B Cell Malignancies	Phase 1/2	Not yet open	2027-06	China
GD2/CD70 Bi-specific CAR-T Cell Therapy NCT05438368 · ClinicalTrials.gov ↗ · Cancer Disease	Phase 1/2	Not yet open	2026-12	China
Immunotherapy Treating GI Cancer NCT03614650 · ClinicalTrials.gov ↗ · Cancer	Phase 1/2	Not yet open	2027-06	China
Antigen-specific T Cells Against Lung Cancer NCT03356808 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 1/2	Not yet open	2027-06	China
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection NCT03217617 · ClinicalTrials.gov ↗ · SCID, X-Linked	Phase 1/2	Not yet open	2027-06	China
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders NCT03123458 · ClinicalTrials.gov ↗ · Immune Related Disorder, Tissue Damage Drug: Clonal fetal MSCs	Phase 1	Not yet open	2026-12	China
Combination Immunotherapy Targeting Melanoma NCT06739226 · ClinicalTrials.gov ↗ · Melanoma	Phase 1/2	Not yet open	2027-06	China
cfMSC Stem Cell Therapy Targeting COPD NCT07477600 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease (COPD) Drug: Clonal fetal MSCs	Phase 1/2	Not yet open	2027-06	China
Direct Lentiviral Injection Gene Therapy for MLD NCT03725670 · ClinicalTrials.gov ↗ · Metachromatic Leukodystrophy (MLD)	Not applicable	Not yet open	2027-05	China
Universal 4SCAR7U Targeting CD7-positive Malignancies NCT05995028 · ClinicalTrials.gov ↗ · T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia	Phase 1	Not yet open	2027-06	China
cfMSC Therapy for Diabetes NCT07495956 · ClinicalTrials.gov ↗ · Type II Diabetes Mellitus	Phase 1/2	Not yet open	2027-06	China
Universal CAR-T Cells Targeting Multiple Myeloma NCT06006741 · ClinicalTrials.gov ↗ · Multiple Myeloma in Remission	Phase 1	Not yet open	2027-06	China
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG NCT07501156 · ClinicalTrials.gov ↗ · Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma	Phase 1/2	Not yet open	2027-06	China
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors NCT03393962 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	By invitation	2025-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shenzhen Geno-Immune Medical Institute trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Clonal fetal MSCs2

Conditions in Shenzhen Geno-Immune Medical Institute trials

39 conditions

Acute Myeloid Leukemia4 B Cell Malignancies3 Solid Tumor3 Multiple Myeloma2Metachromatic Leukodystrophy (MLD)2Sarcoma2Osteoid Sarcoma2Ewing Sarcoma2T-cell Acute Lymphoblastic Leukemia2T-cell Acute Lymphoblastic Lymphoma2NK Cell Lymphoma2Autoimmune Diseases2X-linked Adrenoleukodystrophy1Plasmacytoma1Glioblastoma of Cerebellum1Breast Cancer1PSMA Positive Tumors or Tumor Tissues1Chronic Granulomatous Disease1Diffuse Intrinsic Pontine Glioma or Glioblastoma1Multiple Myeloma or Plasmacytoma1Beta-Thalassemia1B Cell Lymphoma (BCL)1B-cell Leukemia1Hemophilia B1

By trial register

Register	Trials	Recruiting
Clinical trials in China	43	0

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Acute Myeloid Leukemia

Sponsor	Trials
The First Affiliated Hospital of Soochow University	14
National Cancer Institute (NCI)	9
Assistance Publique - Hôpitaux de Paris	7
First Affiliated Hospital of Zhejiang University	6
Taiho Oncology	5
Peking University People's Hospital	5
Zhejiang University	5
Institut Paoli-Calmettes	5
Gruppo Italiano Malattie EMatologiche dell'Adulto	5
Stichting Hemato-Oncologie voor Volwassenen Nederland	4

Sponsors with the most current trials registered for this condition.

Questions about Shenzhen Geno-Immune Medical Institute trials

How many clinical trials does Shenzhen Geno-Immune Medical Institute sponsor?

Shenzhen Geno-Immune Medical Institute is the lead sponsor of 43 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Shenzhen Geno-Immune Medical Institute trials recruiting?

Not at the moment. None of its 43 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Which drugs is Shenzhen Geno-Immune Medical Institute testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Clonal fetal MSCs (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shenzhen Geno-Immune Medical Institute clinical trials